Next, we asked whether the dependence of A375X1 melanoma cells on ALK could be exploited to overcome BRAF inhibitor resistance and we treated the cells with three different ALK inhibitors (Crizotinib, Ceritinib and ASP3026) alone or in combination with PLX4032. This evidence concerns the gene BRAF and melanoma.